Due to COVID-19 we are now offering TeleHealth Office Visits via video or phone call. Learn More >
We have prepared for the Coronavirus (COVID-19). We have updated policies to protect our patients and staff. Learn more.
  • ArrayPharmacy
  • call for care 214.379.2700

    Choice Cancer Care is here for you 9AM – 5PM Monday – Friday

    Inquiring after hours? Complete our contact form and we will be in touch as soon as possible.


  • Patientportal

    Access Your Portal To Health at Choice Cancer Care.

    Learn more about becoming a CCC Patient, including insurance information and patient rights, or login to access your personal portal for in-depth information about your health.

    LoginSign UpLearn More

  • Patientforms
  • get a second opinion

    Recent Diagnosis? Gain Confidence With A Second Opinion.

    Find out what to ask your doctor, what a second opinion could mean for you, and take the steps to get you on the right path to treat your cancer.

    Complete this form for a no obligation consultation:

    • certified

      Choice Cancer Care is proud to be recognized by the Quality Oncology Practice Initiative (QOPI®) for excellence in quality, and safety in the administration of cancer care.

      Learn More

    Surviving Lung Cancer through Immunotherapy

    Immunotherapy in advanced non-small cell lung cancers has helped to extend the overall and progression-free survival in some patients without compromising their quality of life. It forces the immune system to control the disease by fighting cell proliferation. Experts have confirmed that patients who have undergone immunotherapy for NSCLC have survived for longer.

    The overall five-year survival rate for advanced non-small cell lung cancer has been less than 5%. But today, a growing proportion of NSCLC patients have lived longer than five years. This indicates that there is a possibility of extending the lives of lung cancer patients using immunotherapies. A randomized trial showed that an average number of patients treated with a single immune therapy (nivolumab) remained alive five years later.

    During a study:

    • The patients subjected to a trial showed an improvement in survival with more than three years of follow-up with the inhibitor pembrolizumab. During the time of treatment, the patients’ tolerability towards the monotherapy regimen was high. The duration of response was high too, with patients who received pembrolizumab for two years stabilizing with no need for additional therapy.

    • Some patients, after getting treatment for two years, also received pembrolizumab as a second course after progression of the disease. This means the cancer cab stabilize after re-exposure.

    • When used alongside chemotherapy in patients with stage IV squamous cell NSCLC, immunotherapy, specifically atezolizumab inhibiting agent, would benefit patients.

    • Although immunotherapy may not eradicate the tumor in some stages of NSCLC, the disease can be controlled in some cases as seen in this trial.

    Researchers may not have identified the features that would help to predict which patients responded to anti-PD-1 therapy during the trial. But they still managed to know the effect of immunotherapy in patients with tumors that had high PD-1 expression.

    Cancer Screening Guidelines

    Screening can help doctors discover and treat some types of cancer early. Usually, cancer treatment is more effective when the disease is detected in its early stages and there could be a better chance of curing the cancer. Some...

    Learn More

    Learn About Your Options

    Your journey with cancer is influenced by several factors. These factors include your overall condition, the specific characteristics of your cancer, and whether the goal of treatment is to eradicate your cancer, stop your cancer from spreading to other areas...

    Learn More